GoodRx (GDRX) — customer relationships that define revenue optionality and concentration risk

GoodRx operates a consumer-facing digital healthcare platform that monetizes through a mix of subscription fees, per-transaction fees from pharmacies/PBMs, and partnerships with pharmaceutical manufacturers and telehealth providers. The company recognizes subscription revenue on a straight-line basis and recognizes transaction-based fees at the point a prescription is filled, while all revenue is U.S.-centric. For investors and operators, the revenue model is structurally diversified but operationally dependent on a small set of distribution partners and manufacturer relationships.
Explore further coverage and relationship analytics at https://nullexposure.com/.

Why the partner map matters for investors

GoodRx’s partner set reveals three defining characteristics of the operating model: recurring subscriptions plus transaction exposure, high dependency on large retail partners, and distribution-critical manufacturer integrations.

Contracting posture: GoodRx runs both subscription contracts (e.g., Gold and Kroger Savings Club, recognized straight-line) and usage-based agreements that pay GoodRx a per-transaction or volume-based fee when consumers redeem codes at pharmacies. This dual posture provides mixed predictability — subscriptions anchor recurring revenue while transaction fees scale with volume.
Concentration and criticality: Public complaints and filings identify Kroger as a disproportionately important retail partner, creating material concentration risk when a single pharmacy chain accounts for a large share of transaction revenue relative to its store count.
Maturity and controls: The company reports all revenue from U.S. customers and maintains a stable external audit relationship, signalling corporate control maturity appropriate for a public company.

If you want a structured, investor-grade dashboard of these relationships, visit https://nullexposure.com/.

Relationship scorecard — what every named partner contributes

Below are concise, plain-English summaries of each relationship surfaced in company filings and public reporting, with source context for verification.

PricewaterhouseCoopers LLP

PwC has been GoodRx’s external auditor since 2018, as disclosed in the company’s FY2024 10‑K filing. (GoodRx FY2024 10‑K)

Pfizer (PFE)

GoodRx is an integrated pricing source for Pfizer at launch, listing over 30 of Pfizer’s essential brands across multiple therapeutic areas, which positions GoodRx as a key consumer pricing channel for Pfizer products. (GoodRx 2025 Q4 earnings call)

Novo Nordisk (NVO)

GoodRx supported the launch of the Wegovy pill by offering the lowest available self-pay price from day one, demonstrating GoodRx’s role as a launch pricing and access partner for manufacturers. (GoodRx 2025 Q4 earnings call; also cited in FY2025 news coverage)

The Kroger Co. / Kroger (KR)

Kroger appears as a strategic retail partner and subscription channel (Kroger Rx Savings Club); a complaint cited publicly alleges Kroger represented less than 5% of accepting pharmacies yet accounted for nearly 25% of GoodRx’s prescription transactions revenue, highlighting acute concentration risk. (GlobeNewswire investor alert, May 2024; related complaint filings, FY2024)

Kroger Pharmacies / Kroger Savings Club

GoodRx launched the RX Smart Saver counter solution at Kroger Pharmacies nationwide and operated the Kroger Rx Savings Club subscription offering, which historically contributed modest subscription revenue but was later sunsetted, affecting subscription trends. (Yahoo Finance coverage and Biospace press release; third-quarter 2023/2024 disclosures)

Amgen (AMGN)

GoodRx expanded affordability and access programs in partnership with Amgen, reinforcing its commercial relationships with large manufacturers to integrate patient savings into platform flows. (Yahoo Finance FY2025 coverage)

Criteo Corp. (CRTO)

Criteo was named in litigation resolving allegations that GoodRx shared user information with advertising partners; a settlement for alleged data sharing with advertisers (including Criteo) was reported at $25 million. (ClassAction.org reporting, FY2026; ConsumerAffairs FY2025 reporting)

Meta / Facebook (META)

Meta was named among advertisers alleged to have received user data from GoodRx; the company agreed to a $25 million settlement to resolve those claims. (ConsumerAffairs and ClassAction.org reporting, FY2025–FY2026)

Google / Google LLC (GOOGL)

Google was similarly named in the data‑sharing lawsuit resolved with a $25 million settlement, an important reputational and compliance event given GoodRx’s prior advertising partnerships. (ConsumerAffairs and ClassAction.org reporting, FY2025–FY2026)

Rite Aid (RAD)

GoodRx quantified the impact of Rite Aid’s bankruptcy and reduced volumes as an estimated $35–$40 million revenue headwind in 2025 for certain integrated savings programs, signaling sensitivity to pharmacy network disruptions. (TradingView reporting on GoodRx Q2 2025 commentary)

vitaCare Prescription Services, Inc.

GoodRx reported that restructuring decisions de‑prioritized the vitaCare solution, which resulted in a $2.5 million decrease in revenue contribution that was offset by other program gains. (Biospace press release; third-quarter 2024 results)

What the constraints reveal about execution risk

The company disclosures and excerpts provide clear operational signals:

Subscription + usage mix: GoodRx earns subscription revenue (GoodRx Gold; Kroger Rx Savings Club explicitly named) and usage-based fees per prescription transaction, creating a hybrid revenue profile that balances recurring cash flow with variable, volume-driven income.
U.S.-only revenue base: All reported revenue is from customers located in the United States, concentrating macro and regulatory risk domestically.
Customer types and role: Primary customers include PBMs, pharmacies, pharma manufacturers and individual consumers, with the company acting principally as a buyer-facing platform for consumers and as a service provider to manufacturers and pharmacies.
Service orientation: Manufacturer partnerships are categorized as services/affordability integrations, reflecting GoodRx’s role in advertising and pricing integration rather than wholesale distribution.

Collectively, these constraints indicate a company with repeatable subscription economics but asymmetric downside when major retail partners or pharmacy networks change behavior.

Investment implications — what to watch next

Concentration is the headline risk. Kroger’s outsized share of prescription transaction revenue (relative to store count) creates exposure to unilateral partner decisions, as described in public complaint filings. Investors should monitor any changes in acceptance by major chains and the company’s success in diversifying transaction partners.
Regulatory and reputational risk is real and quantified. The $25 million settlement over historical data-sharing claims with Meta, Google and Criteo is a tangible expense and a governance signal; ongoing privacy controls and vendor oversight are material to valuation.
Revenue durability depends on balancing subscriptions and transactional volume. Subscriptions provide baseline predictability, but transaction fees and manufacturer integrations drive scale — watch subscription retention, transaction fill rates, and manufacturer launch pipelines (Pfizer, Novo Nordisk, Amgen).

For an investor-grade breakdown of counterparty concentrations and contractual exposures, access the full relationship intelligence at https://nullexposure.com/.

GoodRx’s partner map is a clear lens into both its monetization strengths (manufacturer integrations, subscription anchors) and material operational risks (retail concentration, pharmacy bankruptcies, and privacy litigation). Investors and operators should track partnership renewals, pharmacy network stability, and the company’s ability to replace lost volumes with diversified channels as the primary indicators of forward revenue resilience.

GDRX customer relationships